Was reading through the criteria for inclusion and exclusion in the trial and it's clear the 'Goldilocks' zone for candidates is quite limited, so I think it's understandable that without a lot of luck, recruitment could be quite staggered. Some of the reasons for exclusion could be removed given a few months of abstinence from certain substances, so maybe some who are keen to participate have to wait for the all-clear period.
See details below.
There appear to be 11 centers actively recruiting now so as is that would only require 4 per facility, although things often don't work out with that even symmetry.
Anyway, currently waiting for the hopefully positive primate results, I think they will bring a broader interest base to ATL-1102, and hence a slightly greater interest in share ownership, as the term platform is enhanced by official FDA safety approval, for everything ATL-1102 (within dose parameters).
These things can discretely leak, not necessarily from the company, creating increased share volumes, and I would like to see people in the not-too-distant future complaining about insider trading, lol.
You know things are going well when people complain about that haha
And, Merry Christmas and a Happy New Year to all.
Description
Key Inclusion Criteria:
Key Exclusion Criteria:
- Has a clinical diagnosis of DMD confirmed by validated genetic testing
- Is considered to be non-ambulatory, defined as unable to walk 10 meters without assistance or help at Screening.
- Male aged 10 to less than 18 years, at the time of Screening.
- Body weight of at least 25 kg at Screening.
- If receiving corticosteroid therapy, therapy was initiated at least six months prior to the baseline visit and a stable daily dose for at least 3 months prior to baseline
- Participant has a Performance of Upper Limb Module for DMD 2.0 (PUL 2.0) Entry Item A score ≥2.
- Able to perform spirometry and has sufficient Respiratory function defined as reproducible percent predicted FVC ≥50%.
- Has adequate cardiac function defined as left ventricular ejection fraction (LVEF) ≥45% by echocardiogram and if receiving cardiac medication, must be currently on a stable regimen and doses of cardiac therapy (at least 3 months prior to baseline Day 1)
- Participant and their parent/guardian/carer are willing and able to comply with scheduled visits, study medication administration and study procedures.
- Participation in another clinical trial (non-interventional) or administration of any investigational product or experimental product within 12 weeks or 5 half-lives (whichever is longer) preceding Day 1.
- Exposure to more than 3 investigational products within the 12 months prior to Day 1.
- History of clinically significant bleeding or coagulation abnormalities or clinically significant abnormal coagulation parameters.
- Currently receiving antiplatelet or anticoagulant therapy or has taken medication with an antiplatelet or anticoagulant effect within 4 weeks prior Day 1
- Any evidence of clinically significant structural or functional heart abnormality (cardiomyopathy that is managed by ACEi or beta blockers is acceptable provided the LVEF inclusion criterion is met).
- Known history of or a positive test for hepatitis B surface antigen (HBsAg), hepatitis C (HCV) antibodies, human immunodeficiency virus (HIV) antibodies at Screening.
- Evidence of renal impairment and/or cystatin C >1.4 mg/L.
- Received a live vaccine (including intranasal influenza vaccine) within 4 weeks prior to Day 1 or planned live vaccination during the study period.
- Asthma (if requiring regular medication), bronchitis/chronic obstructive pulmonary disease (COPD), bronchiectasis, emphysema, pneumonia or the presence of any non-DMD respiratory illness that affects PEF and FVC or other respiratory measures.
- Requires day-time assisted mechanical or non-invasive ventilation (NIV) (night time NIV is permitted).
- Chronic use (daily intake >14 days), within one month of Day 1, of beta-2 agonists or any use of other bronchodilating medication (e.g., inhaled steroids, sympathomimetics, anticholinergics).
- Used carnitine, creatine, glutamine, oxatomide, idebenone or other forms of coenzyme Q10 or vitamin E or any other nutritional or antioxidant supplements or herbal medicines or anabolic steroids other than standard corticosteroids or puberty testosterone supplementation within 4 weeks of Day 1.
- Has an increased risk for opportunistic infections or systemic medical conditions resulting in significantly compromised immune system function
- Forums
- ASX - By Stock
- For General Information
Was reading through the criteria for inclusion and exclusion in...
- There are more pages in this discussion • 89 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.6¢ |
Change
-0.001(1.30%) |
Mkt cap ! $68.51M |
Open | High | Low | Value | Volume |
7.9¢ | 7.9¢ | 7.6¢ | $15.61K | 200K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 110000 | 7.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.0¢ | 138642 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 110000 | 0.077 |
1 | 49195 | 0.076 |
2 | 113467 | 0.075 |
1 | 200000 | 0.072 |
1 | 20000 | 0.071 |
Price($) | Vol. | No. |
---|---|---|
0.080 | 138642 | 4 |
0.081 | 120000 | 1 |
0.083 | 206000 | 2 |
0.085 | 250000 | 2 |
0.087 | 25001 | 1 |
Last trade - 12.51pm 06/05/2024 (20 minute delay) ? |
|
|||||
Last
7.9¢ |
  |
Change
-0.001 ( 1.28 %) |
|||
Open | High | Low | Volume | ||
7.9¢ | 7.9¢ | 7.9¢ | 6979 | ||
Last updated 12.03pm 06/05/2024 ? |
Featured News
PER (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online